Kuitunen Ilari, Uimonen Mikko M, Ponkilainen Ville T, Mattila Ville M
Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
Department of Pediatrics, Mikkeli Central Hospital, Porrassalmenkatu 35-37, 50100, Mikkeli, Finland.
Child Adolesc Psychiatry Ment Health. 2023 Mar 9;17(1):35. doi: 10.1186/s13034-023-00584-0.
Social restrictions due to COVID-19 have impacted the everyday life of adolescents and young adults, with increased levels of stress and anxiety being reported. Therefore, we report primary care visits due to mental health problems and the use of psychotropic medication in Finland.
We conducted a nationwide register-based study and included primary care visits with mental health problems (F*-class ICD-10 diagnosis) for patients aged 15-24 years. We calculated incidence for visits and used incidence rate ratios (IRR) for comparisons. Psychotropic medication purchases for patients aged 13-24 years were included. Annual psychotropic medication user prevalence per 1000 was calculated and prevalence rate ratios (PRR) with 95% confidence intervals (CI) were used for comparisons. The years 2020 and 2021 were compared to the pre-pandemic reference year 2019.
A total of 396534 visits to primary care due to mental health problems were included. Annual visit incidences per 1000 were 151.7 in 2019, 193.6 in 2020, and 306.7 in 2021, indicating a 28% (IRR 1.28, CI 1.27-1.29) increase from 2019 to 2020 and a 102% (IRR 2.02, CI:2.01-2.04) increase from 2019 to 2021. Highest reported increases in 2020 were sleeping disorders (IRR 1.79, CI 1.72-1.87) and anxiety disorders (IRR 1.39, CI 1.37-1.42). Prevalence of antidepressant use increased by 25% (PRR 1.25, CI 1.23-1.26) in 2021. An increase was also seen in the use of antipsychotics (+ 19%, PRR 1.19. CI 1.16-1.21).
The COVID-19 pandemic increased the need for mental health services and medication among Finnish adolescents and young adults. Our health care system needs the capacity to manage the increased number of visits, and we must be better prepared for future crises.
由于新冠疫情实施的社交限制措施影响了青少年和青年的日常生活，据报道他们的压力和焦虑水平有所上升。因此，我们报告了芬兰因心理健康问题进行的初级保健就诊情况以及精神药物的使用情况。
我们开展了一项基于全国登记系统的研究，纳入了年龄在15至24岁、因心理健康问题（国际疾病分类第十版F*类诊断）进行的初级保健就诊。我们计算了就诊发病率，并使用发病率比（IRR）进行比较。纳入了13至24岁患者的精神药物购买情况。计算了每1000人中精神药物使用者的年患病率，并使用患病率比（PRR）及95%置信区间（CI）进行比较。将2020年和2021年与疫情前的参考年份2019年进行比较。
共纳入了396534次因心理健康问题进行的初级保健就诊。2019年每1000人的年就诊发病率为151.7，2020年为193.6，2021年为306.7，这表明从2019年到2020年增加了28%（IRR 1.28，CI 1.27 - 1.29），从2019年到2021年增加了102%（IRR 2.02，CI：2.01 - 2.04）。2020年报告增加最多的是睡眠障碍（IRR 1.79，CI 1.72 - 1.87）和焦虑症（IRR 1.39，CI 1.37 - 1.42）。2021年抗抑郁药的使用患病率增加了25%（PRR 1.25，CI 1.23 - 1.26）。抗精神病药物的使用也有所增加（+19%，PRR 1.19，CI 1.16 - 1.21）。
新冠疫情增加了芬兰青少年和青年对心理健康服务和药物的需求。我们的医疗保健系统需要有能力应对增加的就诊人数，并且我们必须为未来的危机做好更充分的准备。
